Zhang Fan, Jia Dongmei, Li Qiqi, Zhang Mengmeng, Liu Hongyun, Wu Xianggen
Department of Pharmacy, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, 266042, China.
Department of Pathology, Qingdao Municipal Hospital, Qingdao, 266011, China.
Pharm Res. 2021 Feb;38(2):347-359. doi: 10.1007/s11095-020-02982-x. Epub 2021 Jan 19.
To formulate a xanthan gum-containing linezolid ophthalmic solution (LZD-XG) as a new antibiotic treatment against ocular bacterial infection.
LZD-XG was prepared and evaluated for its in vitro/in vivo ocular tolerance, in vitro/in vivo antibacterial activity, and in vivo ocular penetration.
The optimized LZD-XG exhibited good in vitro/in vivo eye tolerance. A prolonged ocular surface residence time of LZD-XG was observed after topical instillation, and the ocular permeation was significantly better for LZD-XG than fora linezolid (LZD) ophthalmic solution. The in vitro antimicrobial activity was significantly better with LZD-XG than with LZD. In vivo evaluation also confirmed a strong therapeutic treatment effect of LZD-XG, as it significantly improved the clinical symptoms, ameliorated the damage of Staphylococcus aureus to ocular tissues, lowered the colony forming unit counts in the cornea, and decreased the myeloperoxidase activity in the cornea.
LZD-XG was deemed a viable ophthalmic solution against ocular bacterial infection due to its excellent in vitro and in vivo characterizations.
制备含黄原胶的利奈唑胺滴眼液(LZD-XG),作为治疗眼部细菌感染的新型抗生素。
制备LZD-XG,并对其体外/体内眼部耐受性、体外/体内抗菌活性及体内眼部渗透性进行评估。
优化后的LZD-XG表现出良好的体外/体内眼部耐受性。局部滴注后观察到LZD-XG在眼表的停留时间延长,且LZD-XG的眼部渗透明显优于利奈唑胺(LZD)滴眼液。LZD-XG的体外抗菌活性明显优于LZD。体内评估也证实了LZD-XG具有强大的治疗效果,因为它显著改善了临床症状,减轻了金黄色葡萄球菌对眼组织的损伤,降低了角膜中的菌落形成单位数量,并降低了角膜中的髓过氧化物酶活性。
由于LZD-XG具有优异的体外和体内特性,它被认为是一种治疗眼部细菌感染的可行滴眼液。